Fda Ok of Sanofi’s type 2 diabetes med iGlarLixi pushed out to November

Fda Ok of Sanofi’s type 2 diabetes med iGlarLixi pushed out to November

At the FDA’s request, Sanofi submits additional information to the agency pertaining to the pen delivery device for its investigational once-daily fixed-dose combination of basal insulin glargine 100 Units/ml and GLP-1 receptor agonist lixisenatide, branded as iGlarLixi, for the treatment of adults with type 2 diabetes.